InMode (INMD)
(Delayed Data from NSDQ)
$16.50 USD
+0.34 (2.10%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $16.47 -0.03 (-0.18%) 7:58 PM ET
2-Buy of 5 2
A Value D Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.50 USD
+0.34 (2.10%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $16.47 -0.03 (-0.18%) 7:58 PM ET
2-Buy of 5 2
A Value D Growth D Momentum B VGM
Zacks News
Here's Why You Should Hold on to Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) owing to its progress with its three-legged strategic, which is driving growth and an impressive 2025 roadmap.
Cardiovascular Systems (CSII) Inks Deal to Enhance Patient Care
by Zacks Equity Research
Cardiovascular Systems' (CSII) investment in CarePICS will advance patient access to the suitable treatment at the right time, thereby leading to improved care and reduced amputations.
CVS Health (CVS) Extends COVID-19 Antibody Testing Nationwide
by Zacks Equity Research
CVS Health's (CVS) antibody test detects for previous infection to COVID-19 and provides results within 15 minutes.
NuVasive's (NUVA) Simply Cervical Artificial Disc Gets FDA Nod
by Zacks Equity Research
NuVasive's (NUVA) Simplify Disc demonstrated an overall clinical success rate nearly 10% higher than the anterior cervical discectomy and fusion.
Medtronic (MDT) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Medtronic's (MDT) ventilator sales are robust and prospects of the Diabetes arm remain strong amid the pandemic.
Abbott's (ABT) DAPT for High Bleeding Risk Gets Europe Nod
by Zacks Equity Research
The studies by Abbott (ABT) show that DAPT can be safely discontinued early with no increased risk in patient adverse events.
Here's Why You Should Retain Abbott Laboratories (ABT) Stock
by Zacks Equity Research
Investors remain optimistic about Abbott Laboratories (ABT) owing to strong growth in its molecular and rapid diagnostics business and progress in diabetes arm.
Abbott's (ABT) BinaxNOW Test Gets FDA's EUA for Self Use
by Zacks Equity Research
According to Abbott (ABT), the self-test BinaxNOW together with vaccines will help Americans get back to their regular daily work with greater confidence.
Syneos Health (SYNH) New Partnership to Enhance Clinical Trials
by Zacks Equity Research
Syneos Health (SYNH) new partnership will extend the company's mission to boost research and enable universal patient and provider access with clinical research services.
The Zacks Analyst Blog Highlights: Quest Diagnostics, LabCorp, InMode, Bioanalytical Systems and Semler Scientific
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Quest Diagnostics, LabCorp, InMode, Bioanalytical Systems and Semler Scientific
Fed Eyes Faster Recovery in 2021: 3 MedTech Stocks to Buy
by Urmimala Biswas
MedTech stocks like INMD, BASI and SMLR are expected to maintain market-beating momentum in 2021.
Will InMode (INMD) Gain on Rising Earnings Estimates?
by Zacks Equity Research
InMode (INMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
InMode (INMD) Moves 6% Higher: Will This Strength Last?
by Zacks Equity Research
InMode (INMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
InMode (INMD) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
InMode's (INMD) Morpheus8 Platform and Morpheus8 Body that use RF fractional technology are expected to have contributed to the company's Q4 top line.
Zacks.com featured highlights include: Azure Power Global, Mueller Industries, H&E Equipment Services, Korea Electric Power and InMode
by Zacks Equity Research
Zacks.com featured highlights include: Azure Power Global, Mueller Industries, H&E Equipment Services, Korea Electric Power and InMode
Stryker (SYK) Buys OrthoSensor to Grow in Sensor Technology
by Zacks Equity Research
Stryker's (SYK) acquisition of OrthoSensor will help surgeons with real-time data-driven solutions and improve patient outcomes.
5 Stocks With Recent Price Strength to Tap Market Rally
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Exagen (XGN) Looks Good: Stock Adds 9.3% in Session
by Zacks Equity Research
Exagen (XGN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Medtronic (MDT) MITG Shows Fast Recovery Amid COVID-19 Woes
by Zacks Equity Research
Medtronic (MDT) expects fiscal third-quarter MITG growth to be in the low single digits.
Zacks.com featured highlights include: MCRI, FCAU, PIPR, NPO and INMD
by Zacks Equity Research
Zacks.com featured highlights include: MCRI, FCAU, PIPR, NPO and INMD
5 Stocks With Recent Price Strength as Indexes Hit Record High
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Is InMode (INMD) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (INMD) Outperforming Other Medical Stocks This Year?
HEXO Catches Eye: Stock Jumps 9.4%
by Zacks Equity Research
HEXO saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Agios' (AGIO) Phase III Study on Mitapivat Meets Primary Goal
by Zacks Equity Research
Agios' (AGIO) phase III ACTIVATE study evaluating mitapivat for addressing PK deficiency in patients with no regular blood transfusions achieves the primary goal.
Surging Earnings Estimates Signal Upside for InMode (INMD) Stock
by Zacks Equity Research
InMode (INMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.